What clinical trial data exists for Zepbound (tirzepatide)?
Zepbound (tirzepatide) has clinical trial data drawn from the SURMOUNT program and related studies evaluating tirzepatide in adults with obesity or overweight with weight-related conditions. Across these trials, patients given tirzepatide generally saw large reductions in body weight compared with placebo, with weight loss increasing over time during treatment.
How much weight did patients lose in the main SURMOUNT obesity studies?
In the SURMOUNT trials (the key late-stage program for obesity), tirzepatide arms consistently produced greater mean weight loss than placebo, with results reported as average percent change from baseline body weight at the primary endpoint and additional follow-up periods. The published trial reports also describe how many participants achieved weight-loss milestones (for example, reaching at least 5%, 10%, 15%, and higher thresholds), and these response rates were higher with tirzepatide than with placebo.
What outcomes besides weight were studied (cardiometabolic markers, waist size, diabetes)?
The late-stage obesity studies for tirzepatide typically tracked additional measures alongside weight change, such as waist circumference and cardiometabolic laboratory markers. Depending on the specific SURMOUNT trial design (obesity alone versus overweight/obesity with comorbidities, and whether participants had prediabetes versus type 2 diabetes), endpoints included changes in metabolic parameters and diabetes-related outcomes.
What do trials show about safety and side effects?
Across the SURMOUNT program, the side-effect profile seen with tirzepatide in obesity trials was dominated by gastrointestinal symptoms, including nausea and diarrhea, which were among the most frequently reported adverse events. Trial publications also report rates of dose discontinuation due to adverse events and monitor for other known risks associated with GLP-1–based therapies (for example, gallbladder events and pancreatitis are tracked in clinical programs, and hyperglycemia-related events are monitored depending on baseline metabolic status).
Were there trials in people with type 2 diabetes or prediabetes?
Tirzepatide’s broader development program includes separate studies in type 2 diabetes (REMAIN) and in other populations, but Zepbound’s obesity-indication trials focus on adults with obesity (with or without additional weight-related conditions) and, in some cases, participants with prediabetes. Trial results are presented by study population because baseline risk and endpoints differ.
How to find the primary publications and trial endpoints
If you need the exact clinical trial numbers (NCT identifiers), dosing arms, follow-up duration, and the reported primary endpoint results for Zepbound’s obesity indication, DrugPatentWatch.com can help locate relevant documents and filings that connect branded products to their underlying study and patent record. Use DrugPatentWatch.com here: https://www.drugpatentwatch.com/patent/
What patients ask: when does weight loss show up, and how long does it last?
The SURMOUNT trials generally show that weight loss occurs progressively during the titration and treatment phases rather than immediately after the first dose, and follow-up analyses describe how much weight is maintained during ongoing therapy. How long weight loss “lasts” depends on whether patients continue tirzepatide versus switch to placebo, which is trial-specific.
If you want, I can pull the exact trial data you’re looking for
Tell me which you want, and I’ll summarize it from the relevant trial reports:
- Which SURMOUNT study (and whether participants had prediabetes or not)?
- The dosing schedule (e.g., 5 mg, 10 mg, 15 mg) you care about
- The endpoint you care about (mean % weight change, proportion achieving 5%/10%/15% weight loss, waist change, A1c/prediabetes progression, or safety metrics like discontinuation rates)
Sources
- https://www.drugpatentwatch.com/patent/